Alpha Cognition Inc. (ACOG) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Alpha Cognition reported revenue of $10.2M. Net income was -$20.7M (a -202.2% net margin), or -$1.18 per diluted share. Gross margin was 94.1% and operating margin was -221.7%. Operating activities generated -$20.4M of cash, leaving -$20.7M of free cash flow. At fiscal year end, Alpha Cognition held $79.7M in total assets against $17.2M in total liabilities, including $66.0M of cash and equivalents.
Open the full interactive Alpha Cognition financials → Quarterly statements, key ratios, valuation history and price charts.
Alpha Cognition Key Stats
| Share Price | $8.80 |
|---|---|
| Market Cap | $191.6M |
| 52-Week Range | $4.50 – $9.75 |
| Shares Outstanding | 21.8 million (basic, 2026 Q2) |
Alpha Cognition Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $10.2M |
| Cost of Goods Sold | — | $603,400 |
| Gross Profit | — | $9.6M |
| Operating Income | -$11.9M | -$22.7M |
| Pre-Tax Income | -$14.6M | -$20.7M |
| Income Tax | — | -$1 |
| Net Income | -$14.6M | -$20.7M |
| Diluted EPS | -$2.02 | -$1.18 |
Alpha Cognition Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.8M | $2.8M | $3.5M | $6.1M |
| Net Income | -$1.3M | -$6.9M | -$6.5M | -$8.8M |
| Diluted EPS | -$0.30 | -$0.39 | -$0.32 | -$0.40 |
Alpha Cognition Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $48.5M | $66.0M |
| Current Assets | $50.3M | $79.0M |
| Total Assets | $50.7M | $79.7M |
| Current Liabilities | $3.4M | $9.1M |
| Total Long-Term Debt | $3.6M | $2.4M |
| Total Liabilities | $9.3M | $17.2M |
| Shareholders' Equity | $41.5M | $62.5M |
Alpha Cognition Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$7.8M | -$20.4M |
| Cash From Investing | -$26,701 | -$293,489 |
| Cash From Financing | $54.9M | $38.2M |
| Free Cash Flow | -$7.8M | -$20.7M |
Figures from Alpha Cognition's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alpha Cognition financials page for every line item.
Alpha Cognition Company Profile
| Ticker | ACOG |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Grapevine, Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001655923 |
Frequently Asked Questions
What was Alpha Cognition's revenue in fiscal 2025?
Alpha Cognition (ACOG) reported revenue of $10.2M for fiscal 2025.
What was Alpha Cognition's net income in fiscal 2025?
Alpha Cognition reported net income of -$20.7M for fiscal 2025.
What was Alpha Cognition's earnings per share (EPS) in fiscal 2025?
Alpha Cognition's diluted EPS was -$1.18 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alpha Cognition generate in fiscal 2025?
Alpha Cognition generated -$20.7M of free cash flow in fiscal 2025.
What was Alpha Cognition's revenue last quarter?
In its most recent reported quarter (2026 Q2), Alpha Cognition reported revenue of $6.1M.
How much debt does Alpha Cognition have?
Alpha Cognition reported $2.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Alpha Cognition are outstanding?
Alpha Cognition reported a weighted average of 21.8 million basic shares outstanding in 2026 Q2.
What is Alpha Cognition's market cap?
Based on its latest closing price, Alpha Cognition (ACOG) has a market capitalization of about $191.6M.
When does Alpha Cognition's fiscal year end?
Alpha Cognition's fiscal year end, as registered with the SEC, is December 31.
Where is Alpha Cognition headquartered?
Alpha Cognition lists its business address in Grapevine, Texas in its SEC filings.
Alpha Cognition Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →